更新于 4月30日

DMPK Research Investigator (Beijing or Shanghai)) (MJ018327)

1.6-2.2萬
  • 上海浦東新區
  • 3-5年
  • 碩士
  • 全職
  • 招1人

職位描述

新藥
Responsibilities:
  • Possess a solid understanding of DMPK principles to guide CROs in completing preclinical DMPK packages that support clinical research or regulatory submissions.
  • Collaborate with colleagues from other R&D departments (Chemistry, Toxicology, Pharmacology, Biomarkers, Clinical, etc.) and global regulatory teams to provide DMPK research support during drug development stages.
  • Assist in the preparation and writing of various DMPK submission documents.
  • Represent the team at internal governance meetings, advise on optimal approaches for regulatory reviews and program progression, and ensure compliance with guidelines from all health authorities concerning Development DMPK matters.
Requirements:
  • Master's or Ph.D. degree in Pharmacokinetics or a related field; at least one year of work experience, with preference given to candidates with DMPK or large molecule PK submission experience.
  • Ability to collaborate cross-functionally with colleagues and work independently.
  • Strong scientific insight and problem-solving skills, meticulous attention to detail, and the ability to learn and adapt quickly.
  • Excellent communication and writing skills in both Chinese and English.
  • Proficiency in using GastroPlus, and familiarity with Excel, Word, PowerPoint, and other office software.
百濟神州全球勝任力 當我們通過以下十二項全球勝任力,展現出 "患者為先"、"無界協作"、"銳意創新 "和 "追求卓越 "的價值觀時,我們就能幫助全世界更多患者獲得更多負擔得起的藥品。 ●團隊協作 ●提供并征求坦誠及可行的反饋 ●自我認知 ●兼容并蓄 ●積極主動 ●開拓精神 ●持續學習 ●擁抱變化 ●結果導向 ●分析性思維/數據分析 ●卓越財務 ●清晰溝通 BeiGene Global Competencies When we exhibit our values of Patients First, Collaborative Spirit, Bold Ingenuity and Driving Excellence, through our twelve global competencies below, we help get more affordable medicines to more patients around the world. ●Fosters Teamwork ●Provides and Solicits Honest and Actionable Feedback ●Self-Awareness ●Acts Inclusively ●Demonstrates Initiative ●Entrepreneurial Mindset ●Continuous Learning ●Embraces Change ●Results-Oriented ●Analytical Thinking/Data Analysis ●Financial Excellence ●Communicates with Clarity 求職者隱私申明: 百濟神州致力于尊重和保護您的個人信息權利,并承諾依據合法、正當、必要和誠信的原則處理您的個人信息(包括個人敏感信息 )。 由于百濟神州在全球范圍內開展業務,我們可能需要基于人力資源管理等合理業務目的而將您的個人信息發送和/或存儲在位于您所在國家以外其他國家(例如:美國)的服務器和數據庫中,詳情參見百濟神州《求職者隱私政策》(百濟神州官網 - 隱私政策 - 求職者隱私政策)。 如您主動向我們提供您的簡歷信息或其他個人信息,則視為您已經充分理解并確認接受百濟神州《求職者隱私政策》內容。如您對此有任何疑問的,請勿提交簡歷信息或其他個人信息。 BeiGene is committed to respect and protect your personal information rights, and will process your personal information, including your sensitive personal information, based on the principles of legality, legitimacy, necessity, and integrity. Due to the reasonable business need for human resource management as a result of BeiGene’s global operation, your personal information may be transferred and/ or stored in a server/database located in a third country (e.g., the United States) other than your own country. For further details, please refer to BeiGene Job Applicant Privacy Policy (BeiGene official website - Privacy Policy - Job Applicant Privacy Policy). If you voluntarily provide your resume or other personal information to us, it is deemed as you have thoroughly acknowledged and accepted BeiGene Job Applicant Privacy Policy. If you have any concern, please DO NOT submit your resume or any other personal information.

工作地點

浦東新區百濟神州(上海)醫藥研發有限公司

職位發布者

張婧媛/百濟神州研發招聘recruiter

剛剛活躍
立即溝通
公司Logo百濟神州北京
About BeiGene BeiGene is a publically traded(BGNE, NASDAQ), globally focused biopharmaceutical company dedicated to becoming a leader in the discovery and development of innovative, molecularly targeted and immuno-oncology drugs for the treatment of cancer. Our cancer biology platform addresses the importance of tumor-immune system interactions and the value of primary tumor biopsies in developing new cancer models. We have a global team of over 200 individuals, including over 150 scientists and clinicians, and a world-renowned scientific advisory board, with deep scientific talent, extensive pharmaceutical experience, and a commitment to improving the lives of cancer patients around the world. Our clinical pipeline is comprised of novel oral small molecules and monoclonal antibodies(mAb) for cancer, including an anti-PD-1 monoclonal antibody, a best-in-class BTK inhibitor, a RAF dimer inhibitor, a best-in-class PARP inhibitor, and a variety of combination clinical studies. In addition, our robust preclinical programs are expected to generate more small molecule and mAb drugs for clinical development in coming years. For more information, please visit our website at www.beigene.com.
公司主頁
久久久久国产一级毛片高清板